11th Global Intellectual Property Convention - Regulatory Provisions of USFDA for Approval of Pharma & Biosimilar Drugs

Jan 18 2019

Barbara Binzak Blumenfeld, and Matthew Fedowitz, shareholders in the FDA & Biotechnology practice and Intellectual Property section, respectively, will present at the 11^th Global Intellectual Property Convention in Bengaluru, India. The plenary session, “Regulatory Provisions of USFDA for Approval of Pharma & Biosimilar Drugs,” will address the regulatory landscape and challenges for sponsors of new drugs, generic drugs, biologics, and “biosimilars” (generic biologics).